Mobile Intervention for Alcohol and Marijuana Use
(SAFERR Trial)
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, it does exclude those who have received substance use treatment in the past 3 months.
What data supports the effectiveness of the treatment for simultaneous alcohol and marijuana use in young adults?
Is the mobile intervention for alcohol and marijuana use safe for humans?
The studies reviewed focus on the risks and consequences of using alcohol and marijuana together, such as increased chances of driving under the influence and experiencing negative effects like blackouts and cognitive issues. However, they do not provide specific safety data on the mobile intervention itself.678910
How is the Mobile Intervention for Simultaneous Alcohol and Marijuana Use in Young Adults different from other treatments?
The Mobile Intervention for Simultaneous Alcohol and Marijuana Use is unique because it specifically targets the simultaneous use of both substances, which is associated with more negative consequences than using either substance alone. This approach may involve using mobile technology to provide real-time support and interventions, making it more accessible and tailored to the individual's daily life compared to traditional treatments.57111213
What is the purpose of this trial?
The goal of this treatment development project is to develop an adaptive ecological momentary intervention (a-EMI) for young adults using marijuana and alcohol that is grounded in self-regulation and social cognitive theories. To determine the most efficacious intervention strategies, the investigators will test variations of intervention components to identify the best combination. The study will take place at the Center for Integrated Health Care Research at Kaiser Permanente Hawaii (KPHI), located in Honolulu (island of Oahu). Following pilot testing with 6 participants, the study team will assess the feasibility and efficacy of intervention components on two primary outcomes (negative consequences and protective behavioral strategies \[PBS\]) using a fractional factorial experimental design, with post-intervention assessment and one- and three-month follow-ups. 136 diverse young adults recruited from KPHI who report current simultaneous alcohol and marijuana (SAM) use will be randomly assigned to one of eight groups, representing experimental conditions that include or do not include intervention strategies focused on craving reduction and PBS. As a result of this process, individual and/or combined components that lead to improved outcomes will be retained in a subsequent randomized controlled trial, while ineffective components will be eliminated.
Research Team
Kristina Phillips, PhD
Principal Investigator
Kaiser Permanente
Eligibility Criteria
This trial is for young adults aged 18-30 in Hawaii who use marijuana and alcohol together, have experienced negative consequences from their use, and are confident they can follow protective strategies. They must have visited Kaiser Permanente Hawaii within the last year, live on O'ahu, and own a smartphone.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Pilot Testing
Pilot testing of the SAFERR a-EMI with 6 participants to assess feasibility and make necessary revisions
Intervention
Participants complete a baseline assessment and are randomly assigned to one of eight conditions. They receive the SAFERR a-EMI intervention, including ecological momentary assessment (EMA) and introduction module
Post-Intervention Assessment
Participants complete a post-intervention assessment to evaluate the efficacy of intervention components
Follow-up
Participants are monitored for safety and effectiveness after treatment with follow-up assessments at one and three months
Treatment Details
Interventions
- Mobile Intervention for Simultaneous Alcohol and Marijuana Use in Young Adults
Find a Clinic Near You
Who Is Running the Clinical Trial?
Kaiser Permanente
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Collaborator